Search
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression
Capivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalTherefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative
N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine
go.drugbank.com/drugs/DB14196ApprovedN-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen. … Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.
Synonyms: N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine, N-Cyclohexyl-N'-phenyl-p-phenylendiamineSulopenem etzadroxil
go.drugbank.com/drugs/DB16335ApprovedInvestigationalSulopenem etzadroxil is a prodrug of the penem antibacterial [sulopenem]. Like other beta-lactam antibacterials, it is a time-dependent inhibitor of bacterial cell wall synthesis.
Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalmaintenance monotherapy resulted in a 22% reduction in the risk of death. … [A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3.
Synonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)ureaClozapine
go.drugbank.com/drugs/DB00363ApprovedInvestigationalClozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. … [L905] Due to its severe adverse effects profile, clozapine is only available through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program.[L905]
Products: Aa-clozapine, CLOZAPIN 25 1A PHARMAAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC. … Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics.
Raltitrexed
go.drugbank.com/drugs/DB00293ApprovedInvestigationalRaltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
Human Rho(D) immune globulin
go.drugbank.com/drugs/DB11597ApprovedHuman Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). … Rho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the Rh0 (D) antigen (D antigen) under the name Rhophylac (IM/IV).
Human cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedHemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use. … Human umbilical cord is a rich source of hematopoietic stem cells and progenitor cells that are capable of proliferation _in vitro_.